SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.139+0.9%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Redman12343/3/2025 3:34:06 PM
6 Recommendations

Recommended By
bobbseytwins2001
CCS648
Davidoff
End2War
Fitzhughlaw

and 1 more member

  Read Replies (1) of 1229
 
First investor analyst conference ever in April? PSS is not doing this without a loaded gun. Two things off hand come to mind. One is with expected UK NICE approval sometime in March or April Anktiva should be available for treatment in 90 days. IBRX is already likely in deep partnership or licensing talks for UK/EMA. Second, we never did find out the breakdown of the Beigene deal for NSCLC P3 trial. Thats a must to breakdown at the conference, and likely very beneficial towards IBRX. I view today’s SP beating as different than some might. Yes the market is reacting to talk of tariffs and
government shutdown, but I think smart shorts are trying to find a exit and Tutes are trying to fill their pockets with shares before ground breaking news at analyst conference.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News